Quethera has secured an undisclosed amount of funding from the University of Cambridge Enterprise Fund III.
Quethera, a pharmaceutical spinout of University of Cambridge, has secured an undisclosed amount of funding from the University of Cambridge Enterprise Fund III.
The fund was launched by Cambridge Enterprise, University of Cambridge’s tech transfer office, and is managed by Parkwalk Advisors.
Quethera is developing a treatment for glaucoma, a disease of the eye that is a leading cause for blindness and particularly affects the elderly population. The development is still in its early-stage and so far has been confined to the lab.
The cash injection will be used to establish operations and conduct further research at Cambridge, and to conduct animal studies. The money will also support the filing of patent applications.
Quethera expects its platform to also herald results for other diseases in the long run.
